Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in the United States, Canada, Europe, the Middle East, Latin America, Asia Pacific and Africa.
Company Growth (employees)
Type
Public
HQ
Aliso Viejo, US
Founded
1960
Size (employees)
21,500 (est)
Valeant Pharmaceuticals International was founded in 1960 and is headquartered in Aliso Viejo, US

Key People at Valeant Pharmaceuticals International

Joe Papa

Joe Papa

CEO

Valeant Pharmaceuticals International Office Locations

Valeant Pharmaceuticals International has an office in Aliso Viejo

Valeant Pharmaceuticals International Data and Metrics

Valeant Pharmaceuticals International Financial Metrics

Valeant Pharmaceuticals International's revenue was reported to be $2.1 b in Q1, 2017
USD

Revenue (Q1, 2017)

2.1 b

Gross profit (Q1, 2017)

1.5 b

Gross profit margin (Q1, 2017), %

72%

Net income (Q1, 2017)

629 m

EBIT (Q1, 2017)

211 m

Market capitalization (18-Aug-2017)

5 b

Cash (31-Mar-2017)

1.2 b
Valeant Pharmaceuticals International's current market capitalization is $5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

5.8 b8.3 b10.4 b9.7 b

Revenue growth, %

43%26%(7%)

Cost of goods sold

1.8 b

Gross profit

3.9 b6.1 b7.9 b

Gross profit Margin, %

68%73%76%

Operating expense total

4.3 b4 b6.4 b

EBIT

(409.5 m)2 b1.5 b

EBIT margin, %

(7%)25%15%

Interest expense

844.3 m

Interest income

8 m

Income tax expense

4 m

Net Income

(863.7 m)912.2 m(287.8 m)(2.4 b)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.8 b2.1 b

Cost of goods sold

634.6 m584 m

Gross profit

2.2 b1.5 b

Gross profit Margin, %

77%72%

R&D expense

101.6 m96 m

General and administrative expense

697.6 m661 m

Operating expense total

799.2 m757 m

EBIT

447.8 m211 m

EBIT margin, %

16%10%

Interest expense

(420.2 m)(474 m)

Interest income

700 k3 m

Income tax expense

(57.4 m)(924 m)

Net Income

122 m276.4 m74.5 m(51.6 m)51.7 m(372.9 m)(676.9 m)(1.9 b)629 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

600.3 m322.6 m597.3 m542 m

Accounts Receivable

1.8 b2.1 b2.7 b2.5 b

Inventories

205 m641.9 m966.4 m1.1 b

Current Assets

3.9 b4.2 b5.5 b5.1 b

PP&E

1.2 b1.3 b1.4 b1.3 b

Goodwill

9.8 b9.3 b18.6 b15.8 b

Total Assets

28 b26.4 b49 b43.5 b

Accounts Payable

327 m398 m433.7 m324 m

Total Debt

17.4 b15.3 b31.1 b1 m

Current Liabilities

2.5 b2.7 b5.3 b3.6 b

Total Liabilities

40.3 b

Additional Paid-in Capital

228.9 m243.9 m304.9 m351 m

Retained Earnings

(3.3 b)(2.4 b)(2.7 b)(5.1 b)

Total Equity

5.2 b5.4 b6 b3.3 b

Debt to Equity Ratio

3.3 x2.8 x5.2 x0 x

Debt to Assets Ratio

0.6 x0.6 x0.6 x0 x

Financial Leverage

5.3 x4.8 x8.1 x13.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

531.2 m808.8 m1.9 b958 m1.4 b1.3 b852.4 m658.5 m1.2 b

Accounts Receivable

1.8 b1.9 b2.1 b2.4 b2.7 b2.7 b2.7 b2.7 b2.1 b

Inventories

942.5 m932.7 m998.9 m1.2 b1.2 b1.3 b1.3 b1.3 b1.1 b

Current Assets

5.2 b4.4 b16.2 b6.3 b7 b6.2 b5.8 b5.7 b5.3 b

PP&E

1.3 b1.3 b1.3 b1.4 b1.4 b1.5 b1.5 b1.5 b1.3 b

Goodwill

9.4 b9.5 b9.2 b17.2 b17.4 b18.6 b18.5 b17.5 b15.8 b

Total Assets

27.9 b27.1 b38.6 b48.3 b48.5 b49 b47.7 b45.8 b42.3 b

Accounts Payable

327.7 m323.3 m352.5 m415.8 m476.8 m438.1 m425.9 m358.7 m368 m

Current Liabilities

2.5 b3.1 b3.1 b4.3 b4.7 b4.6 b4.2 b3.9 b4.2 b

Additional Paid-in Capital

212.2 m240.2 m260.9 m234 m244.6 m351.6 m380.4 m325.9 m374 m

Retained Earnings

(3.2 b)(2.9 b)(2.3 b)(2.4 b)(2.3 b)(3.1 b)(3.4 b)(4.6 b)(4.5 b)

Total Equity

5.4 b5.2 b6.6 b6.6 b6.5 b5.8 b5.4 b4.3 b4 b

Financial Leverage

5.2 x5.2 x5.9 x7.4 x7.5 x8.5 x8.8 x10.7 x10.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(863.7 m)912.2 m(287.8 m)(2.4 b)

Accounts Receivable

(260 m)

Inventories

(120 m)(170 m)(280 m)(164 m)

Cash From Operating Activities

1 b2.3 b2.2 b2.1 b

Purchases of PP&E

(115.3 m)(291.6 m)(235.2 m)(235 m)

Cash From Investing Activities

(5.4 b)(99.7 m)(15.6 b)(125 m)

Long-term Borrowings

(6.3 b)(3.9 b)(2.1 b)(2.4 b)

Cash From Financing Activities

4 b(2.4 b)13.7 b(2 b)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

122 m276.4 m74.5 m(51.6 m)51.7 m(372.9 m)(676.9 m)(1.9 b)629 m

Depreciation and Amortization

635 m

Inventories

(12.1 m)(41.5 m)(38.5 m)(48.3 m)(45.6 m)(85.9 m)(145.1 m)(166.3 m)(38 m)

Cash From Operating Activities

376 m618.7 m491.1 m410.5 m736.5 m558.1 m1 b1.6 b954 m

Purchases of PP&E

(113.5 m)(39.6 m)(65.8 m)(46.8 m)(51.1 m)(62.3 m)(128.3 m)(181.1 m)(38 m)

Cash From Investing Activities

(266.4 m)756.3 m(11.2 b)(2.6 b)(156.2 m)(112 m)(62.1 m)(131.4 m)1.1 b

Long-term Borrowings

(120.3 m)(1.6 b)(1.1 b)(247.9 m)(29 m)(425.6 m)(1.3 b)(1.9 b)(7.6 b)

Cash From Financing Activities

(156.6 m)(1.1 b)12.3 b1.3 b(108.5 m)259.2 m(692.3 m)(1.4 b)(1.4 b)
USDY, 2017

Revenue/Employee

98.1 k

Financial Leverage

10.6 x

Valeant Pharmaceuticals International Market Value History

Traffic Overview of Valeant Pharmaceuticals International

Valeant Pharmaceuticals International Online and Social Media Presence

Valeant Pharmaceuticals International News and Updates

Drug Makers Accused of Fixing Prices on Insulin

A lawsuit claims Sanofi, Novo Nordisk and Eli Lilly raised prices at the expense of patients’ health.

Breakingviews: How Valeant Had a Bright Idea but Took It Too Far

The pharmaceutical aimed to grow through acquisitions and price increases, but ran into a wall of opposition. Now it and other drug makers are facing the industry’s limitations.

Breakingviews: Takeda’s Bid for Cancer Drug Maker Looks Expensive

The Japanese pharmaceutical offers to buy Ariad Pharmaceuticals for $5.2 billion, about 75 percent above the price where the biotech’s shares were trading.

Specialty Pharmacies Say Benefit Managers Are Squeezing Them Out

The pharmacies, which often sell high-cost drugs for rare diseases to relatively few patients, complain of being cut from benefit managers’ networks.

Japan's Takeda to Buy U.S. Cancer Drug Maker Ariad in $5.2 Billion Deal

Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.

Street Scene: Documents Open Curtain on Boardroom Drama at Valeant

A Senate committee report shows how the hedge fund billionaire William Ackman turned on a chief executive he had long supported.
Show more

Valeant Pharmaceuticals International Company Life and Culture

You may also be interested in